Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 12/20 | 1.00 |
| ▸ | S1PR4 | O95977 | 9/20 | 1.00 |
| ▸ | S1PR2 | O95136 | 6/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.88 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.72 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.72 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.72 |
| ▸ | GPR183 | P32249 | 1/20 | 0.72 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.72 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.62 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14801617 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL17083799 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL29518569 | 0.94 | ENPP2 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| Fingolimod SCHEMBL15515724 | 0.89 | S1PR1 (0.85) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL15868568 | 0.88 | S1PR1 (0.79) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL20740319 | 0.88 | S1PR1 (0.79) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| Phosphoric Acid SCHEMBL6507536 | 0.85 | S1PR1 (0.78) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL7614950 | 0.84 | S1PR1 (0.88) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL3390328 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL3393539 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315735-A4 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | claimed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | claimed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | claimed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | claimed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | claimed |
| US-10111841-B2 | Stabilization of alcohol intoxication-induced cardiovascular instability | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170020826-A1 | STABILIZATION OF ALCOHOL INTOXICATION-INDUCED CARDIOVASCULAR INSTABILITY | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-01-26 | — | — | US | disclosed |
| US-20130079309-A1 | Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-03-28 | — | — | US | disclosed |
| EP-1315735-A4 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | ALPP, PPIP5K2, ALPI | S1PR1 382/4885S1PR3 520/4885S1PR4 499/4885 |
| US-20130079309-A1 | Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.